India - English - Central Drugs Standard Control Organization

nicholas - black cohosh ext.,soy isoflavones,cal.carbonate,vit.d3 - tab - 20mg,75mg,150mg,100iu. - 10

United States - English - NLM (National Library of Medicine)

hevert pharmaceuticals llc - black cohosh (unii: k73e24s6x9) (black cohosh - unii:k73e24s6x9), anamirta cocculus seed (unii: 810258w28u) (anamirta cocculus seed - unii:810258w28u), cypripedium parviflorum var. pubescens root (unii: 21y9gz1lza) (cypripedium parviflorum var. pubescens root - unii:21y9gz1lza), strychnos ignatii seed (unii: 1nm3m2487k) (strychnos ignatii seed - unii:1nm3m2487k), passiflora incarnata flowering top (unii: clf5yfs11o) (passiflora incarnata flowering top - unii:clf5yfs11o), platinum (unii: 49dfr088my) (p - black cohosh 4 [hp_x] in 2 ml - 1.1 hevert® calmvalera™ comp. is a homeopathic drug indicated for the treatment of nervous disorders, such as restlessness and sleep disorders, mild depressive states, and mental exhaustion. hevert® calmvalera™ comp. is contraindicated in patients with known hypersensitivity to lady's slipper or orchids, or to any of its ingredients. animal reproduction studies have not been performed with hevert® calmvalera™ comp. or any of its ingredients. there are not adequate and well-controlled studies in pregnant women. hevert® calmvalera™ comp. should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. no non-teratogenic effects are known. no recognized use in labor or delivery. it is not known whether hevert® calmvalera™ comp. is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when hevert® calmvalera™ comp. is administered to a nursing woman. safety and effectiveness in pediatric patients have not been established.

New Zealand - English - Medsafe (Medicines Safety Authority)

blackmores (nz) ltd - symphytum officinale 350 mg/g (root liquid extract, equivalent to fresh root 175 mg/g) - topical cream - 350 mg/g - active: symphytum officinale 350 mg/g (root liquid extract, equivalent to fresh root 175 mg/g) excipient: arachis oil cetostearyl alcohol glyceryl monostearate r07338 special ph fragrance lavender oil phenonip ppg-1-peg-9 lauryl glycol ether purified water siberian fir needle oil sodium hydroxide sodium laurilsulfate - indicated for short term use - up to 7 days. indicated for the temporary relief of back, joint and muscle pain, tenderness and swelling associated with soft tissue injury such as sprains, strains, contusions caused by minor injury/trauma. indicated to aid recovery by reducing symptoms of pain, swelling and stiffness. seek medical advice if symptoms persist for more than seven days. do not use for more than 3 weeks.

Australia - English - Department of Health (Therapeutic Goods Administration)

mms international health products pty ltd - black cohosh powder -

Bangladesh - English - DGDA (Directorate General of Drug Administration)

ibn sina pharmaceuticals industries ltd.(herbal) - black cohosh - capsule

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - acalabrutinib, quantity: 100 mg - capsule, hard - excipient ingredients: iron oxide yellow; indigo carmine aluminium lake; pregelatinised starch; sodium starch glycollate type a; gelatin; shellac; silicified microcrystalline cellulose; propylene glycol; titanium dioxide; iron oxide black; magnesium stearate - calquence is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. calquence is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy.,calquence is indicated for the treatment of patients with chronic lymphocytic leukaemia(cll)/small lymphocytic lymphoma (sll).

Australia - English - Department of Health (Therapeutic Goods Administration)

homart pharmaceuticals pty ltd - calcium carbonate, quantity: 900 mg (equivalent: calcium, qty 360 mg); colecalciferol, quantity: 5 microgram - capsule, soft - excipient ingredients: yellow beeswax; white beeswax; titanium dioxide; glycerol; gelatin; purified water; lecithin; soya oil; d-alpha-tocopherol - maintain/support bone health ; aids/assists healthy bone development/growth/building ; maintain/support bone strength ; a diet deficient in calcium can lead to osteoporosis in later life. calcium may help prevent osteoporosis when dietary intake is inadequate ; vitamin d helps calcium absorption (or words of like intent) and a diet deficient in calcium can lead to osteoporosis in later life ; helps prevent dietary (state vitamin/mineral/nutrient) deficiency

Australia - English - Department of Health (Therapeutic Goods Administration)

blackmores ltd - calcium ascorbate dihydrate, quantity: 50 mg (equivalent: ascorbic acid, qty 41.31 mg); pyridoxine hydrochloride, quantity: 50 mg (equivalent: pyridoxine, qty 41.1 mg); heavy magnesium oxide, quantity: 440 mg (equivalent: magnesium, qty 265.3 mg); magnesium phosphate pentahydrate, quantity: 175 mg (equivalent: magnesium, qty 36.2 mg); manganese amino acid chelate, quantity: 40 mg (equivalent: manganese, qty 4 mg); colecalciferol, quantity: 0.0025 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; carnauba wax; magnesium stearate; hypromellose; microcrystalline cellulose; tartaric acid; macrogol 8000; titanium dioxide; indigo carmine; purified talc; polyvinyl alcohol; macrogol 3000; lecithin; maize starch; silicon dioxide; dl-alpha-tocopherol; sucrose; hydrolysed gelatin; hydrogenated soya oil - maintain/support general health and wellbeing ; maintain/support bone health ; maintain/support heart health ; decrease/reduce/relieve muscle cramps ; maintain/support muscle health ; maintain/support muscle function ; decrease/reduce/relieve muscle tension/stiffness ; maintain/support nervous system health

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

rosemont pharmaceuticals ltd - vitamin a; ergocalciferol; choline chloride; cyanocobalamin - oral emulsion - 500unit/1ml ; 80unit/1ml ; 30mg/1ml ; 2.5microgram/1ml

European Union - English - EMA (European Medicines Agency)

astrazeneca ab - acalabrutinib - leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll).calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.